Kornimate/medical-research-clean huggingface dataset:
2-d and 3-d laparoscopic hysterectomy

Conditions: Fibroma, Bleeding

Summary: background: no randomised trials have been conducted, and only a single retrospective study exists comparing 3d and 2d laparoscopic hysterectomy. in that study, operative time for hysterectomy was significantly lower for 3d compared to 2d conventional laparoscopy. complication rates were similar for the two groups. thus, although one out of nine women is hysterectomized and although laparoscopy is one of the recommended routes of surgery, evidence whether to choose 2d laparoscopy, 3d laparoscopy is sparse. objective: to compare pain and recurrence to usual activity level. secondary to compare complications during the operation, postoperative complications, time to return to work, length of hospital stay and operative time. design: investigator-initiated, blinded, randomised controlled trial. intervention description: operative procedures follow the same principles and the same standard whether the surgeon's vision is 2d or 3d. trial size roskilde/herlev hospital, denmark: 200 patients in each arm of the study.


Eligibility criteria:
inclusion criteria: * all patients referred for laparoscopic hysterectomy with or without bilateral salpingectomy or bilateral salpingooophorectomy for benign indications. exclusion criteria: * women not suitable for laparoscopic hysterectomy including: * ultrasound appraisal of uterus weight \> 1000 gram * need for prolapse surgery and therefore indication for vaginal hysterectomy. * inability to give informed consent

Keywords: imaging, three-dimensional hysterectomy laparoscopic hysterectomy
computational anatomy in surgery for childhood tumours and malformations

Conditions: Malformation; Tumor; Paediatric Surgery; 3D Imaging

Summary: this study is part of the launch of a multidisciplinary project called imag2, for image-guided minimally invasive surgery. it involves collaboration between the radiology and surgery teams at necker hospital and the image processing and interpretation (tii) team at the ltci at télécom paristech. to make a decision, surgeons need access to a 3d model reflecting the anatomy of the specific patient and its pathological variations. patient-specific 3d reconstruction provides a significant improvement, leading to a precise assessment of the malformation or tumour and its relationship with surrounding organs, nerves and vessels. it allows the surgeon to simulate a pre-operative procedure, which is a definite advantage in terms of safe, effective and curative surgery, particularly in oncology. mri has been chosen as the basic imaging technique because of its non-irradiating nature and the current lack of 3d mri reconstruction technology. the study aims to provide an aid to diagnosis and surgical planning by developing dedicated methods and algorithms for segmenting not only the tumour but also the main anatomical components surrounding the tumour from 3d mri imaging data. the imaging will be performed on a 3 tesla mri. the data will be that required for diagnosis and surgical planning, acquired on a routine clinical basis with an expected benefit for patients.


Eligibility criteria:
to be included, patients must meet the following criteria: * patient aged between 5 months and 17 years * patient with a confirmed diagnosis of : * abdomino-pelvic tumour * pelvic malformation * patient whose parents or legal guardians have read, accepted and signed the study consent form * patients whose parents or legal guardians are beneficiaries of a social security scheme. to be included, control patients (patients other than those suffering from an abdomino-pelvic tumour or malformation) must meet the following criteria: * patient aged between 5 months and 17 years inclusive. * a patient being followed in the visceral surgery department for a pathology other than tumour or malformation, and requiring mri as part of his or her diagnosis, extension assessment or monitoring. * patient whose parents or legal guardians have read, accepted and signed the study consent form. * patient whose parents or guardians are beneficiaries of a social security scheme. non inclusion criteria : patients * patient with a contraindication to mri: metallic ocular foreign body, pacemaker, mechanical cardiac valve, old vascular clips on cerebral aneurysm, etc. * patient having participated in a therapeutic clinical trial involving a new molecule in the 30 days prior to inclusion. controls : * patient with a contraindication to mri: ocular metallic foreign body, pacemaker, cardiac mechanical valve, old vascular clips on cerebral aneurysm, etc. * patient having participated in a therapeutic clinical trial involving a new molecule in the 30 days prior to inclusion.
evaluation of local delivery of aloe vera gel as an adjunct to non-surgical treatment in patients with chronic periodontitis

Conditions: Chronic Periodontitis

Summary: aim of the current study was to evaluate the effect of aloe vera gel as an adjunct to scaling and root planing (srp) in the management of chronic periodontitis.

the effect of aloe vera on treatment of chronic periodontitis will be evaluated in a randomized, controlled clinical trial. thirty patients with mild to moderate chronic periodontitis were divided into 2 groups: group 1 (test): will include 15 patients treated with srp followed by application of aloe vera gel in the periodontal pockets at day 1 and after 1 and 2 weeks, and group 2 (control) which includes 15 patients treated with srp only.

Eligibility criteria:
inclusion criteria: * systemically healthy individuals. * patients with mild to moderate chronic periodontitis (cal 1-4mm) according to the american academy of periodontology classification exclusion criteria: * smoking and alcoholism. * patients with systemic illnesses (i.e., diabetes mellitus, cancer, human immunodeficiency syndrome, bone metabolic diseases, or disorders that compromise wound healing, radiation, or immunosuppressive therapy, conditions leads to xerostomia). * patients on any medication affecting the periodontium. * lactating, pregnant or menopausal females. * patients with parafunctional habits. * patients with poor oral hygiene.
jskn003 in platinum-resistant, relapsed epithelial ovarian cancer

Conditions: Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers

Summary: this study is a randomized, open-label, controlled, phase iii study to evaluate the efficacy and safety of jskn003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.


Eligibility criteria:
inclusion criteria: * voluntary participation and written informed consent. * ≥18 years; * histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. * confirmed platinum-resistant relapse. * according to recist 1.1 criteria, there must be at least one measurable lesion in the baseline. * expected survival of more than 3 months. * ecog performance status score of 0 or 1. * adequate organ function. * capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures. exclusion criteria: * primary platinum-refractory disease. * active central nervous system metastases. * uncontrolled pleural effusion. * previous treatment with topoisomerase i inhibitor adcs. * other malignant tumors within 5 years. * interstitial pneumonia/lung disease requiring systemic corticosteroids or suspected interstitial pneumonia/lung disease. * uncontrolled comorbidities. * toxicity from previous anti-cancer treatments not recovered to ctcae grade ≤1. * history of allogeneic bone marrow or organ transplantation. * allergic reactions or hypersensitivity to antibody drugs. * conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.

Keywords: jskn003-306
25-g vitrectomy with ranibizumab or triamcinolone acetonide on pdr in china-randomized clinical trial

Conditions: Proliferative Diabetic Retinopathy

Summary: proliferative diabetic retinopathy(pdr) is the leading cause of visual loss in diabetic patients. operation is an efficient method to treat pdr. anti-vascular endothelial growth factor (anti-vegf) can be used as an adjuvant therapy which can make operation more easy.

proliferative diabetic retinopathy(pdr) is the leading cause of visual loss in diabetic patients. the operation indication includes non-absorbed vitreous haemorrhage, dense bleeding in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal detachment combined break, severe progressive fiber vascular proliferation and vitreous haemorrhage combined with early iris neovascularization. due to vegf levels rise in vitreous cavity of pdr patients, some inflammatory cytokines involved in, make easy bleeding during surgery and heavier inflammatory reaction postoperation,thus affecting the curative effect of the operation. ranibizumab as angiogenesis inhibitors, has widely applied in the treatment of age-related macular degeneration, won the recognition of ophthalmologists. some scholars try to expand the application in diabetic macular edema, also obtained the good curative effect.some scholars also applied the angiogenesis inhibitors to the diabetes retinopathy before surgery in the hope to reduce the occurrence of intraoperative bleeding.compared with bevacizumab, the short half-life of lucentis, and thus reduce the inhibition of vegf system risk. in this project, the investigators will inject lucentis into vitreous cavity before surgery of pdr, and observe the effect and complications of the operation, compared with triamcinolone acetonide group(the control group); at the same time the cytokines level of vegf, pigment epithelium-derived factor (pedf), epidermal growth factor (egf), transforming growth factor-beta (tgf-beta), interleukin 6 (il - 6) and interleukin 8 (il - 8) will be detected before and after pretreatment with lucentis or triamcinolone acetonide, and the cytokines concentration change will be compared between two groups, the mechanism of pdr will be further clarified and theoretical basis for looking for treatment strategies will be a set.

Eligibility criteria:
inclusion criteria: * type ii diabetes mellitus with diabetic retinopathy * vitreous hemorrhage/proliferation of retinal/tractional detachment of retina exclusion criteria: * fasting blood-glucose more than 8mmol/ml * subjects who have operation on vitreous before * accompany with other ophthalmology diseases except cataract * history of vitrectomy surgery in the study eye * previous subfoveal focal laser photocoagulation in the study eye * previous participation in a clinical trial (for either eye) * previous subfoveal focal laser photocoagulation in the study eye * other diseases cannot afford vitrectomy

Keywords: lucentis ranibizumab triamcinolone acetonide vitrectomy pdr 25-gauge vitrectomy
katguide method versus conventional method at insertion of chest tube

Conditions: Pneumothorax; Hydrothorax; Hemothorax; Empyema; Chylothorax

Summary: the purpose of this study is to investigate whether if katguide (a new developed medical device) improves the placing of a large bore chest tube in the pleural cavity compared to the conventional method.


Eligibility criteria:
inclusion criteria: * patients with pneumothorax in the upper pleural space or fluid in the lower pleural space. * indication for upper or lower placement of a single chest tube in the pleural cavity * 18 years of age or older exclusion criteria: * fertile women * patients who can not give written or verbal consent to participate * if there is no time or possibility to inform the patient * patients who already has a large bore chest tube * patients with long lasting (\>14 days) or chronic chest tube * patients with both fluid and air in the pleural cavity * patients where "the safe area" (front axillary fold, ic 4-5) can not be used for chest tube insertion

Keywords: chest tube placement mal positioning
gi-reasons- a trial of gi safety of celecoxib compared with non-selective nonsteroidal antiinflammatory drugs (nsaids)

Conditions: Osteoarthritis

Summary: this study investigates if celebrex has a lower incident of gastrointestinal events than other nsaids in subjects with osteoarthritis.


Eligibility criteria:
inclusion criteria: * male or female patients of at least 55 years of age with a clinical diagnosis of oa who are expected to require daily prescription anti-inflammatory analgesic therapy for arthritis symptom management and for whom either celecoxib or a nsnsaid is an appropriate treatment option. exclusion criteria: * gi ulcer hemorrhage or active gd ulceration less than 90 days prior to screening visit. * patients with a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.

Keywords: gi events in patients with moderate gi risk treated with nsaids
follow-up of prader willi syndrome infants treated by oxytocin and comparison with not-treated infants.

Conditions: Prader-Willi Syndrome

Summary: the objective of this study is to collect data on tolerance and effects of early treatment with oxytocin in children with prader willi syndrome aged from 3 to 4 years and to compare these infants with not treated age-matched infants with prader willi syndrome.

in accordance with recommendations of regulatory authorities, we want to collect long term data of patients treated with oxytocin before the age of 6 months. moreover clinical observations of these infants support long term effects on communication skills, global development and behaviour.

Eligibility criteria:
inclusion criteria: * infants with prader willi syndrome (genetic diagnosis confirmed) * for treated group : infant included in the ancient study * for not treated group: infant never treated with oxytocin exclusion criteria: * subject involved in another search including an exclusion period still in progress at the time of inclusion. * impossibility to give parents or legal guardian informed information * no coverage by a social security scheme * refusal of parents or legal representative to sign consent. if a patient has a contraindication to magnetic resonance imaging, it may be included in the study but magnetic resonance imaging will not be performed.

Keywords: prader-willi oxytocin communication skills oral skills brain activity hormonal disease
switching to duloxetine to ameliorate ssri-induced sexual dysfunction

Conditions: Depression

Summary: sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (ssris). the hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an ssri and experiencing treatment-related sexual dysfunction will experience less sexual dysfunction if they are switched to duloxetine, and 2. they will experience either improved antidepressant response or no loss of antidepressant response.

in this study, subjects suffering from depression or dysthymia and experiencing treatment-emergent sexual dysfunction from an ssri are switched from their ssri to duloxetine to determine whether or not they experience improved sexual function and equal or improved antidepressant response. study subjects are assigned to receive open label duloxetine for 12 weeks at either 60mg per day or 120mg per day after discontinuing their current antidepressant

Eligibility criteria:
inclusion criteria:: * age 18 - 65 inclusive * able to read and understand informed consent * informed consent given * currently being treated with an ssri for depression or dysthymia * currently suffering from treatment-emergent sexual dysfunction attributable to the ssri * have normal safety lab values at screen * if currently taking medication to improve sexual performance, willing to discontinue the drug for the duration of the study * female subjects of child bearing age need to use an acceptable form of birth control throughout the study exclusion criteria:- being pregnant, breastfeeding, or planning to become pregnant within 4 months * suffering from psychotic, substance abuse, bipolar, or organic mental disorder, ocd, panic disorder, or personality disorder severe enough to interfere with study participation * suffer from an unstable or serious medical disorder * having a medical disorder that could be the cause of the sexual dysfunction * taking a medication that is metabolized by hepatic enzyme cyp2d6 * having used a maoi within 15 days of proposed start of duloxetine treatment * having a known hypersensitivity to duloxetine or any of its ingredients * having taken viagra or related drug within 3 months prior to starting ssri treatment * requiring ongoing treatment with a mood stabilizer (anticonvulsant) or antipsychotic medication
oct-angiography and adaptive optics in patients with memory impairment

Conditions: Amnesia; Alzheimer Disease; Lewy Body Disease; Parkinsons Disease With Dementia

Summary: studies suggest an association between retinal abnormalities and ncd (neuro cognitive disorders) whether they are linked to proven or prodromal alzheimer's disease (amci : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or lewy body diseases. these retinal anomalies objectified by oct-a (optical coherence tomography angiography) and adaptive optics (ao) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying ncd. no study to date has studied the retina and its vessels in ncd using adaptive optics. in this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (oct-a and ao), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with ncd. we will compare the parameters in oct-a and ao between patients with ncd and controls without ncd (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of ncd.


Eligibility criteria:
inclusion criteria: * patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint exclusion criteria: * pregnant or lactating women * history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis) * history of retinal pathology * ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder. * history of taking ethambutol for more than 2 months * history of takingsynthetic antimalarial for more than 2 years * mini mental state score (mms) and / or montreal cognitive assessment (moca) \<10 for patients and 26 for accompanying persons * mri contraindication (for patients only)

Keywords: oct-a adaptative optics
stereotaxis and chronic total occlusion

Conditions: Chronic Total Coronary Occlusion

Summary: wire-crossing of a chronic total coronary occlusion (cto) is time-consuming and limited by the amount of contrast agent and time of radiation exposure. magnetic wire navigation might accelerate wire-crossing by maintaining a coaxial vessel orientation. this study compares magnetic with conventional wire navigation for recanalization of ctos.


Eligibility criteria:
inclusion criteria: * symptomatic * preserved wall motion or viable myocardium * chronic total occlusion exclusion criteria: * chronic renal failure * prior allergic reactions against contrast agent * hyperthyreosis * claustrophobia * pregnancy * contraindications to aspirin or clopidogrel
consolidation chemotherapy after autologous stem cell transplantation for lymphoid malignancies

Conditions: Effects of Chemotherapy

Summary: to imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation

patients with relapsed or refractory lymphoma will be included. all patients will undergo pbsc mobilization with ctx and g-csf. after sucessful collection of cd34+ over 1x109/l, autologous stem cel ltransplantation with bu-cy-e conditioning will be given. two months after auto-hsct, a pet-ct will be performed and all patients with cr, cru and pr will recieved 3 cycles of mini-bu-cy-e as consolidation 3, 6 and 9 months after auto-hsct. for patients with sd or pd after auto-hsct will refered to the allogeneic transplantatio program and take off the study.

Eligibility criteria:
inclusion criteria: * patients with relapsed or refracotry nhl or hd: pr or sd after first line salvage chemotherapy; * ecog: 0-2 * tbil \< 1.5x uln and ast/alt \<2.5x uln * with informed consent exclusion criteria: * life expectancy \< 3 months * women in pregnancy * uncontrollable infection disease * serum cr \>400mmol/l * uncontroled diabetis and heart disease

Keywords: lymphoma, consolidation chemotherapy, auto-hsct
expression of toll-like receptors 2 and 4 in asthmatic patients.

Conditions: Asthma

Summary: introduction: recently it has involved the role of tlr (toll-like receptors) in the pathogenesis of asthma. tlrs are a family of proteins responsible for the recognition of pathogen-associated molecular patters (pamps). the possible role that tlrs play in ige-dependent asthma (not eosinophilic) and its recognition as a new endotype asthma, could open new therapeutic expectations. objective: to analyze the expression of tlr 2 and 4 in monocytes/ macrophages and neutrophils in peripheral blood and induced sputum from asthmatic patients

the investigators studied patients with asthma. all patients underwent the same day an induced sputum, pulmonary function studies, fractional exhaled nitric oxide, blood total ige and skin test by prick technique. asthmatic patients were classified according to the criteria of the gina 2012. the cellular composition was analyzed by flow cytometry. expression of tlr2 and tlr4 were analyzed using monoclonal antibodies conjugated with fluorochromes appropriate.

Eligibility criteria:
inclusion criteria: * adults with persistent asthma (defined as per the global initiative for asthma management (gina) criteria) exclusion criteria: * if they had a respiratory tract infection or asthma exacerbation within 30 days prior to inclusion * if they were receiving oral steroids or immunosuppressive treatments.

Keywords: asthma toll like receptor innate immunity